8,521 reports of this reaction
6.4% of all SOMATROPIN reports
#3 most reported adverse reaction
DEVICE BREAKAGE is the #3 most commonly reported adverse reaction for SOMATROPIN, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 8,521 FDA adverse event reports linking SOMATROPIN to DEVICE BREAKAGE. This represents approximately 6.4% of all 133,576 adverse event reports for this drug.
SOMATROPIN has an overall safety score of 78 out of 100. Patients taking SOMATROPIN who experience device breakage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEVICE BREAKAGE is moderately reported among SOMATROPIN users, representing a notable but not dominant share of adverse events.
In addition to device breakage, the following adverse reactions have been reported for SOMATROPIN:
The following drugs have also been linked to device breakage in FDA adverse event reports:
DEVICE BREAKAGE has been reported as an adverse event in 8,521 FDA reports for SOMATROPIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEVICE BREAKAGE accounts for approximately 6.4% of all adverse event reports for SOMATROPIN, making it one of the most commonly reported side effect.
If you experience device breakage while taking SOMATROPIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.